Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3076-3083

  Entenza, J M ^a   Que, Y A ^a   Vouillamoz, J ^a   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

8 METHOXYQUINOLONE DERIVATIVE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GENE PRODUCT; MOXIFLOXACIN; PROTEIN GRLA; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; AORTA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENDOCARDITIS; GENE MUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, MICROBIAL; ENDOCARDITIS, BACTERIAL; FLUOROQUINOLONES; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RATS; SPLEEN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0034775484     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3076-3083.2001     Document Type: Article

References (34)

1. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis
2. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
3. Vancomycin pharmacokinetics in normal and morbidly obese subjects
4. The chemistry and biological profile and trovafloxacin
5. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination
6. Influence of pretreatment duration of infection on the efficacies of various antibiotic regimens in experimental streptococcal endocarditis
7. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone
8. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy
9. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability
10. Efficacy of levofloxacin in the treatment of experimental endocarditis caused by viridans streptococci
11. Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis
12. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: Lack of in vivo efficacy in experimental endocarditis
13. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-usceptible or -resistant Staphylococcus aureus
14. Efficacy of trovafloxacin in treatment of experimental staphylococcal and streptococcal endocarditis
15. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
16. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci
17. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: Novel pleiotropic effects on quinolone and coumarin activity
18. Natural history of aortic valve endocarditis in rats
19. In vitro activity of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections
20. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus
21. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, spartloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
22. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoro-quinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency
23. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
24. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
25. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
26. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
27. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus
28. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones
29. Phenotypic tolerance: The search for β-lactam antibiotics that kill nongrowing bacteria
30. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections
31. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones
32. Microbiological test to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus